EORTC participation at ISPOR Europe 2025 conference

The European Organisation for Research and Treatment of Cancer (EORTC) is proud to participate in ISPOR Europe 2025, the leading global conference on health economics and outcomes research (HEOR), taking place from 9 to 12 November in Glasgow, UK. 

This year's presence reflects EORTC's ongoing commitment to bridging the gap between clinical trial outcomes and real-world value assessment. At the core of this effort is the organisation's focus on one of the most pressing challenges in healthcare decision-making: managing and reducing uncertainties between research evidence and clinical practice. 

Denis Lacombe, EORTC Chief Executive Officer, will moderate the plenary session "Pragmatic Trials — Bridging Research and Real-World Care". The discussion will explore how more pragmatic elements in trial designs can overcome the limitations of traditional explanatory studies, improve patient-centred outcomes, and generate evidence that better reflects real-life clinical settings. 

In addition to its leadership role in the plenary, EORTC will contribute to the scientific programme with three poster presentations: 

• Fabio Borges: Uncertainties in regulatory benefit-risk decision-making for innovative anticancer therapies: preliminary result s from a 2011-2024 review of extensions of indications 

Analysing evidence gaps in European assessments of oncology drugs seeking extensions of indication and highlighting factors that contribute to uncertainty in regulatory evaluations. 

• Maria Teixeira: Patient-reported outcomes used for regulatory approval of oncology medicinal products in the EU between 2021 and 2024: a review update 

Highlighting progress in Patient-Reported Outcome (PRO) use but as well as persistent challenges in translating this evidence into label claims, reinforcing the need for greater methodological rigour. 

• Claire Piccinin: Use of EORTC item lists for patient-reported outcome measurement in industry-sponsored research: A three-year snapshot of study characteristics. 

A review of the use of EORTC item lists in industry-sponsored studies over a 3-year period, highlighting study attributes and trends. 

For more information about the ISPOR Europe 2025 program, please click here. 

We look forward to connecting with you in Glasgow. 

The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.